tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRDN Stock Latest News

Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook
RatingsViridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline Outlook
15d ago
VRDN
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics
PremiumRatings
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian Therapeutics
22d ago
VRDN
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial Position
PremiumRatings
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial Position
23d ago
VRDN
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
23d ago
VRDN
Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studies
PremiumThe Fly
Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studies
23d ago
VRDN
Viridian Therapeutics files automatic mixed securities shelf
PremiumThe FlyViridian Therapeutics files automatic mixed securities shelf
1M ago
VRDN
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
Premium
Ratings
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
2M ago
VRDN
Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
Premium
The Fly
Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
2M ago
AMGN
VRDN
Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
PremiumRatings
Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
2M ago
VRDN
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo
PremiumThe Fly
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo
2M ago
VRDN
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
PremiumRatings
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
2M ago
VRDN
Viridian Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Viridian Therapeutics Reports Q2 2025 Financial Results
2M ago
VRDN
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
PremiumRatingsViridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
2M ago
VRDN
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
Premium
Ratings
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
2M ago
VRDN
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments
Premium
Ratings
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments
2M ago
VRDN
Viridian Therapeutics reports Q2 EPS ($1.00), consensus (97c)
PremiumThe Fly
Viridian Therapeutics reports Q2 EPS ($1.00), consensus (97c)
2M ago
VRDN
Viridian Therapeutics: Strategic Partnership and Promising Clinical Developments Drive Buy Rating
PremiumRatings
Viridian Therapeutics: Strategic Partnership and Promising Clinical Developments Drive Buy Rating
2M ago
VRDN
Viridian Therapeutics: Strategic Partnership and Market Potential Drive Buy Rating Despite Risks
PremiumRatings
Viridian Therapeutics: Strategic Partnership and Market Potential Drive Buy Rating Despite Risks
2M ago
VRDN
Viridian Therapeutics: Strategic Partnership and Financial Milestones Drive Buy Rating
PremiumRatings
Viridian Therapeutics: Strategic Partnership and Financial Milestones Drive Buy Rating
2M ago
VRDN
Viridian Therapeutics Partners with Kissei for Japan Market
PremiumCompany AnnouncementsViridian Therapeutics Partners with Kissei for Japan Market
2M ago
8K
VRDN
Viridian enters veligrotug, VRDN-003 collaboration and license pact with Kissei
Premium
The Fly
Viridian enters veligrotug, VRDN-003 collaboration and license pact with Kissei
2M ago
VRDN
Viridian Therapeutics price target lowered to $38 from $41 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target lowered to $38 from $41 at Evercore ISI
3M ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >